The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.
Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease
Open accessAbstract
The etiology of dry eye disease (DED) is complex and not yet fully understood, but the disease is now recognized as being associated with ocular surface inflammation. The latest advances in the understanding of the pathophysiology of DED have directed the focus of recent drug development to target the inflammatory pathways involved in the disease. Lifitegrast is a novel small molecule integrin antagonist that inhibits T cell-mediated inflammation by blocking the binding of two important cell surface proteins (lymphocyte function-associated antigen 1 and intercellular adhesion molecule 1), thus lessening overall inflammatory responses. This review highlights the role of T cells and integrins in the inflammatory process involved in the pathophysiology of DED and outlines the scientific rationale for the role of lifitegrast. In addition, the preclinical development, pharmacological properties, clinical efficacy, and safety of lifitegrast are described.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Small-molecule inhibitors of protein–protein interactions: progressing towards the dream
Arkin, M. R., & Wells, J. A. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1343 · Cited by 1,705
Gaudana, R., Ananthula, H. K., Parenky, A., & Mitra, A. K. (2010) · The AAPS Journal · doi:10.1208/s12248-010-9183-3 · Cited by 1,406
Cited by
Targeting integrin pathways: mechanisms and advances in therapy
Pang, X., He, X., Qiu, Z., Zhang, H., Xie, R., Liu, Z., Gu, Y., Zhao, N., Xiang, Q., & Cui, Y. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01259-6 · Cited by 1,275
Lu, H., Zhou, Q., He, J., Jiang, Z., Peng, C., Tong, R., & Shi, J. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-00315-3 · Cited by 891
Dua, H. S., Said, D. G., Messmer, E. M., Rolando, M., Benitez-del-Castillo, J. M., Hossain, P. N., Shortt, A. J., Geerling, G., Nubile, M., Figueiredo, F. C., et al. (2018) · Progress in Retinal and Eye Research · doi:10.1016/j.preteyeres.2018.04.003 · Cited by 404
Lifitegrast for the Treatment of Dry Eye Disease
Holland, E. J., Luchs, J., Karpecki, P. M., Nichols, K. K., Jackson, M. A., Sall, K., Tauber, J., Roy, M., Raychaudhuri, A., & Shojaei, A. (2017) · Ophthalmology · doi:10.1016/j.ophtha.2016.09.025 · Cited by 200
Self-citationWu, H., Xu, Y., Cai, M., You, L., Liu, J., Dong, X., Yin, X., Ni, J., & Qu, C. (2022) · Pharmaceutics · doi:10.3390/pharmaceutics14061277 · Cited by 18
Metadata
- Authors
- Perez, V. L., Pflugfelder, S. C., Zhang, S., Shojaei, A., & Haque, R.
- Venue
- The Ocular Surface
- Publisher
- Elsevier BV
- Published
- 2016-04
- Volume
- 14
- Issue
- 2
- Pages
- 207-215
- ISSN
- 1542-0124 (ISSN-L)
- OpenAlex
- W2293232340
- Cited by
- 201
- References
- 2
- FWCI
- 20.56
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. https://app.cochat.ai/papers/10.1016/j.jtos.2016.01.001
- The paper
- Perez, V. L., Pflugfelder, S. C., Zhang, S., Shojaei, A., & Haque, R. (2016). Lifitegrast, a Novel Integrin Antagonist for Treatment of Dry Eye Disease. The Ocular Surface. https://doi.org/10.1016/j.jtos.2016.01.001
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.
